Renin-Angiotensin System

Overview

The renin-angiotensin-aldosterone system (RAAS) is a peptide hormone cascade that serves as one of the body's principal regulators of arterial blood pressure, intravascular volume, and sodium-potassium balance. It exemplifies how sequential enzymatic cleavage of peptide precursors can generate multiple bioactive fragments with distinct and sometimes opposing physiological effects.

The classical RAAS pathway proceeds through a series of well-characterized enzymatic steps: renin cleaves angiotensinogen to produce angiotensin I, which is then converted to angiotensin II by angiotensin-converting enzyme (ACE). Angiotensin II is the primary effector peptide, exerting potent vasoconstrictive, pro-inflammatory, and aldosterone-stimulating effects. However, the modern understanding of RAAS has expanded considerably to include counter-regulatory axes, local tissue systems, and additional bioactive angiotensin fragments.

The Classical Cascade

Step 1: Renin Release

Renin is an aspartyl protease synthesized and stored in the juxtaglomerular cells of the renal afferent arteriole. Three primary stimuli trigger renin secretion:

• Reduced renal perfusion pressure — sensed directly by baroreceptors in the afferent arteriole
• Decreased sodium chloride delivery — detected by the macula densa cells of the distal tubule
• Sympathetic nervous system activation — beta-1 adrenergic receptor stimulation of juxtaglomerular cells

Renin release is inhibited by angiotensin II (negative feedback), high blood pressure, and atrial natriuretic peptide (ANP).

Step 2: Angiotensin I Formation

Renin cleaves the leucine-valine bond in angiotensinogen, a 452-amino-acid glycoprotein produced constitutively by the liver, to generate the decapeptide angiotensin I (Ang I). Angiotensin I has minimal biological activity of its own and serves primarily as a substrate for ACE.

Step 3: Angiotensin II Generation

Angiotensin-converting enzyme (ACE), a zinc metallopeptidase anchored to the surface of pulmonary endothelial cells (and present in many other tissues), removes two amino acids from angiotensin I to produce the octapeptide angiotensin II (Ang II). The pulmonary vascular bed, with its enormous endothelial surface area, is the primary site of this conversion, though local ACE activity in the heart, kidneys, brain, and vasculature contributes to tissue-level Ang II production.

Notably, ACE also degrades bradykinin, linking the RAAS to the kinin-kallikrein system. This dual function explains why ACE inhibitors both reduce Ang II production and increase bradykinin levels.

Step 4: Angiotensin II Actions

Angiotensin II acts through two primary GPCR subtypes:

AT1 Receptor — mediates the majority of classical RAAS effects:

• Vasoconstriction of arterioles, raising systemic vascular resistance
• Stimulation of aldosterone secretion from the adrenal cortex, promoting sodium and water retention
• Enhancement of sympathetic nervous system activity
• Stimulation of antidiuretic hormone (vasopressin) release
• Promotion of cardiac and vascular smooth muscle hypertrophy
• Pro-inflammatory and pro-fibrotic effects via NF-kB and TGF-beta signaling
• Stimulation of thirst and sodium appetite via central nervous system AT1 receptors

AT2 Receptor — generally opposes AT1 effects:

• Vasodilation via nitric oxide and bradykinin release
• Anti-proliferative and anti-fibrotic actions
• Promotion of apoptosis in certain cell types
• Potential neuroprotective effects

AT2 receptor expression is high in fetal tissues and decreases after birth but is re-expressed in pathological conditions such as heart failure and tissue injury, suggesting a role in compensatory or repair responses.

Step 5: Aldosterone

Aldosterone, a mineralocorticoid hormone released from the adrenal zona glomerulosa in response to Ang II and elevated potassium, acts on the distal nephron to increase sodium reabsorption and potassium excretion. Water follows sodium osmotically, expanding intravascular volume and raising blood pressure.

The Counter-Regulatory Axis: ACE2/Ang(1-7)/Mas

A major expansion of RAAS understanding came with the characterization of ACE2, a homolog of ACE that cleaves angiotensin II into the heptapeptide angiotensin(1-7). This fragment activates the Mas receptor, producing effects that broadly oppose the AT1 axis:

• Vasodilation
• Anti-inflammatory effects
• Anti-fibrotic actions
• Cardioprotective signaling

The ACE2/Ang(1-7)/Mas axis is now recognized as a critical counterbalance to excessive AT1 activation. Disruption of this balance — for example, by viral downregulation of ACE2 — can shift the system toward unchecked vasoconstriction, inflammation, and fibrosis.

Local Tissue RAAS

Beyond the circulating endocrine system, many tissues express a complete local RAAS with paracrine and autocrine functions:

• Heart — cardiac RAAS drives pathological remodeling in heart failure
• Kidneys — intrarenal RAAS regulates glomerular hemodynamics and tubular sodium handling independently of circulating levels
• Brain — central RAAS modulates blood pressure set points, thirst, and sympathetic outflow
• Adipose tissue — adipocyte RAAS contributes to metabolic syndrome and insulin resistance

Local Ang II concentrations can be significantly higher than circulating levels, underscoring the importance of tissue-level RAAS activity in disease pathology.

Pharmacological Modulation

The RAAS is one of the most therapeutically targeted peptide systems in medicine:

• ACE inhibitors (enalapril, lisinopril) — block Ang I to Ang II conversion and reduce bradykinin degradation
• Angiotensin receptor blockers (ARBs) (losartan, valsartan) — selectively block the AT1 receptor
• Direct renin inhibitors (aliskiren) — block the initial enzymatic step
• Mineralocorticoid receptor antagonists (spironolactone, eplerenone) — block aldosterone's effects
• ARNI (angiotensin receptor-neprilysin inhibitor) — sacubitril/valsartan combines AT1 blockade with neprilysin inhibition to enhance natriuretic peptide levels

Relevance to Peptide Research

The RAAS demonstrates several principles central to peptide biology:

• Proteolytic processing of a single precursor generating multiple bioactive fragments
• Opposing receptor subtypes (AT1 vs. AT2) providing regulatory balance
• Local tissue production versus systemic endocrine signaling
• Cross-talk between peptide systems (RAAS and kinin-kallikrein)

Related Topics

• Angiotensin II — the primary RAAS effector peptide
• Kinin-Kallikrein System — bradykinin pathway linked via ACE
• Nitric Oxide System — vasodilatory pathway modulated by AT2 and Mas receptors
• Peptides in Cardiology — cardiovascular applications of peptide research